Twin Capital Management Inc. Has $3.15 Million Stake in Gilead Sciences, Inc. $GILD

Twin Capital Management Inc. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 15.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,337 shares of the biopharmaceutical company’s stock after selling 4,987 shares during the quarter. Twin Capital Management Inc.’s holdings in Gilead Sciences were worth $3,145,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GoalVest Advisory LLC lifted its holdings in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences during the third quarter worth approximately $26,000. Harbor Asset Planning Inc. bought a new position in shares of Gilead Sciences in the second quarter valued at approximately $27,000. Howard Hughes Medical Institute acquired a new position in shares of Gilead Sciences in the 2nd quarter worth approximately $30,000. Finally, Putney Financial Group LLC grew its position in Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 94 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Kelly A. Kramer sold 2,805 shares of the company’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a total value of $356,515.50. Following the completion of the transaction, the director directly owned 1,339 shares of the company’s stock, valued at approximately $170,186.90. This represents a 67.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $150.00, for a total value of $17,346,000.00. Following the completion of the transaction, the chief executive officer owned 613,912 shares of the company’s stock, valued at $92,086,800. The trade was a 15.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 373,037 shares of company stock worth $50,731,512 in the last ninety days. 0.27% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on GILD shares. Wolfe Research lifted their price objective on Gilead Sciences from $150.00 to $155.00 and gave the company an “outperform” rating in a research report on Wednesday, January 28th. Truist Financial lifted their price target on Gilead Sciences from $140.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Citigroup raised their price objective on shares of Gilead Sciences from $140.00 to $156.00 and gave the company a “buy” rating in a research report on Tuesday, January 27th. Finally, Daiwa Securities Group upped their target price on shares of Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $136.73.

Gilead Sciences Price Performance

Shares of GILD opened at $152.50 on Friday. The stock’s 50-day moving average price is $127.38 and its two-hundred day moving average price is $120.91. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The stock has a market cap of $189.20 billion, a P/E ratio of 23.64, a price-to-earnings-growth ratio of 0.79 and a beta of 0.36. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $153.13.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.